Recent Company News

• 07:09 AM ET Mar 31, 2026
  

  Phase III clinical trial of Anbenitamab Injection (KN026) combined with Docetaxel for Injection (Albumin-bound) (HB1801) meets primary endpoint

• 11:21 PM ET Mar 26, 2026
  

  StreetAccount Summary - Asia Sector Highlights

• 11:08 PM ET Mar 26, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 12:31 AM ET Mar 25, 2026
  

  StreetAccount Metrics Recap - CSPC Pharmaceutical Group FY Earnings (HK$8.41, +0.08)

• 12:26 AM ET Mar 25, 2026
  

  CSPC Pharmaceutical Group reports FY net income attributable CNY3.88B vs FactSet CNY4.99B [25 est, CNY3.45-6.38B] (HK$8.41, +0.08)

• 08:05 PM ET Mar 23, 2026
  

  Alphamab Oncology doses first patient in phase III clinical study of KN026 for adjuvant treatment of HER2+ BC (HK$8.04, 0.00)

• 11:11 PM ET Mar 22, 2026
  

  StreetAccount Consensus Metrics Preview - CSPC Pharmaceutical Group FY Earnings (HK$8.31, -0.49)

• 06:35 AM ET Mar 20, 2026
  

  NMPA approves clinical trial of CSPC Pharmaceutical Group's SYH2082 for weight management (HK$8.80, 0.00)

• 07:07 AM ET Mar 16, 2026
  

  CSPC Pharmaceutical Group obtains NMPA approval for clinical trials of PDE4Binhibitor (SYH2059 powder for inhalation) for interstitial lung disease (HK$9.03, 0.00)

• 06:46 AM ET Mar 06, 2026
  

  CSPC Pharmaceutical Group obtains US FDA approval for clinical trials of SYH2059 powder for inhalation